Is Cancer a Risk Factor for Cognitive Decline in Late Life?

Gerontology

Volumn 61, Issue 6, 2015, Pages 561-566

  Small, Brent J ^a,b   Scott, Stacey B ^a   Jim, Heather S L ^b   Jacobsen, Paul B ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Chemobrain; Cognition; Older adults

Indexed keywords

BRAIN; CANCER RISK; CANCER SURVIVOR; COGNITIVE DEFECT; DEMENTIA; GERIATRIC DISORDER; GERONTOLOGIST; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MENTAL PERFORMANCE; PRIORITY JOURNAL; REVIEW; AGE; COGNITION DISORDERS; NEOPLASMS; PSYCHOLOGY; RISK FACTOR;

AGE FACTORS; COGNITION DISORDERS; HUMANS; NEOPLASMS; RISK FACTORS;

EID: 84946476376     PISSN: 0304324X     EISSN: 14230003     Source Type: Journal    
DOI: 10.1159/000381022     Document Type: Review

References (44)

1. Lindenberger U: Human cognitive aging: corriger la fortune? Science 2014; 346: 572-578.
2. Wefel JS, et al: Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin 2015; 65: 123-138.
3. Lichtman SM, Hurria A, Jacobsen PB: Geriatric oncology: an overview. J Clin Oncol 2014; 32: 2521-2522.
4. Rowland JH, Bellizzi KM: Cancer survivorship issues: life after treatment and implications for an aging population. J Clin Oncol 2014; 32: 2662-2668.
5. Rowland JH, et al: Cancer survivorship research in Europe and the United States: where have we been, where are we going, and what can we learn from each other? Cancer 2013; 119(suppl 11):2094-2108
6. Hewitt M, Greenfield SE (eds): From Cancer Patient to Cancer Survivor: Lost in Transition. Washington, The National Academies Press, 2005.
7. LiveStrong Foundation: How cancer has affected post-treatment survivors: a LiveStrong report. 2010. www.livestrong.org.
8. Vardy J, Rourke S, Tannock IF: Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol 2007; 25: 2455-2463.
9. Saykin AJ, et al: Neuroimaging biomarkers and cognitive function in non-CNS cancer and its treatment: current status and recommendations for future research. Brain Imaging Behav 2013; 7: 363-373.
10. Koppelmans V, et al: Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy. Breast Cancer Res Treat 2012; 132: 1099-1106.
11. Cimprich B, et al: Prechemotherapy alterations in brain function in women with breast cancer. J Clin Exp Neuropsychol 2010; 32: 324-331.
12. Backman L, et al: Linking cognitive aging to alterations in dopamine neurotransmitter functioning: recent data and future avenues. Neurosci Biobehav Rev 2010; 34: 670-677.
13. Phillips KM, et al: Cognitive functioning after cancer treatment: a 3-year longitudinal comparison of breast cancer survivors treated with chemotherapy or radiation and noncancer controls. Cancer 2012; 118: 1925-1932.
14. Schagen SB, et al: Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst 2006; 98: 1742-1745.
15. Collins B, et al: Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psychooncology 2009; 18: 134-143.
16. Jim HS, et al: Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol 2012; 30: 3578-3587.
17. Wefel JS, et al: International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 2011; 12: 703-708.
18. McGinty HL, et al: Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Support Care Cancer 2014; 22: 2271-2280.
19. Holland J, Bandelow S, Hogervorst E: Testosterone levels and cognition in elderly men: a review. Maturitas 2011; 69: 322-337.
20. Mandelblatt JS, Jacobsen PB, Ahles T: Cognitive effects of cancer systemic therapy: implications for the care of older patients and survivors. J Clin Oncol 2014; 32: 2617-2626.
21. Ahles TA, et al: Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 2010; 28: 4434-4440.
22. Stern Y: Cognitive reserve. Neuropsychologia 2009; 47: 2015-2028.
23. Anstey KJ, et al: Self-reported history of chemotherapy and cognitive decline in adults aged 60 and older: the PATH Through Life Project. J Gerontol A Biol Sci Med Sci 2013, Epub ahead of print.
24. Mandelblatt JS, et al: Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity? J Clin Oncol 2014; 32: 1909-1918.
25. Shaffer VA, et al: Chemotherapy was not associated with cognitive decline in older adults with breast and colorectal cancer: findings from a prospective cohort study. Med Care 2012; 50: 849-855.
26. Koppelmans V, et al: Late effects of adjuvant chemotherapy for adult onset non-CNS cancer; cognitive impairment, brain structure and risk of dementia. Crit Rev Oncol Hematol 2013; 88: 87-101.
27. Heflin LH, et al: Cancer as a risk factor for long-term cognitive deficits and dementia. J Natl Cancer Inst 2005; 97: 854-856.
28. Khan NF, et al: Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study. Br J Cancer 2011; 105(suppl 1):S29-S37.
29. Roe CM, et al: Alzheimer disease and cancer. Neurology 2005; 64: 895-898.
30. Roe CM, et al: Cancer linked to Alzheimer disease but not vascular dementia. Neurology 2010; 74: 106-112.
31. Farrer LA, et al: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A metaanalysis. JAMA 1997; 278: 1349-1356.
32. Small BJ, et al: Apolipoprotein E and cognitive performance: a meta-analysis. Psychol Aging 2004; 19: 592-600.
33. Ahles TA, et al: The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology 2003; 12: 612-619.
34. Andreotti C, et al: Cancer, coping, and cognition: a model for the role of stress reactivity in cancer-related cognitive decline. Psychooncology 2014, Epub ahead of print.
35. Stawski RS, Mogle JA, Sliwinski MJ: Associations among fluid and crystallized cognition and daily stress processes in older adults. Psychol Aging 2013; 28: 57-63.
36. Karlamangla AS, et al: Biological correlates of adult cognition: midlife in the United States (MIDUS). Neurobiol Aging 2014; 35: 387-394.
37. Nelson WL, Suls J: New approaches to understand cognitive changes associated with chemotherapy for non-central nervous system tumors. J Pain Symptom Manage 2013; 46: 707-721.
38. Ram N, et al: Developmental change and intraindividual variability: relating cognitive aging to cognitive plasticity, cardiovascular lability, and emotional diversity. Psychol Aging 2011; 26: 363-371.
39. Rebok GW, et al: Ten-year effects of the advanced cognitive training for independent and vital elderly cognitive training trial on cognition and everyday functioning in older adults. J Am Geriatr Soc 2014; 62: 16-24.
40. Colcombe SJ, et al: Cardiovascular fitness, cortical plasticity, and aging. Proc Natl Acad Sci USA 2004; 101: 3316-3321.
41. Small BJ, et al: Do changes in lifestyle engagement moderate cognitive decline in normal aging? Evidence from the Victoria Longitudinal Study. Neuropsychology 2012; 26: 144-155.
42. Kesler S, et al: Cognitive training for improving executive function in chemotherapytreated breast cancer survivors. Clin Breast Cancer 2013; 13: 299-306.
43. Ferguson RJ, et al: Development of CBT for chemotherapy-related cognitive change: results of a waitlist control trial. Psychooncology 2012; 21: 176-186.
44. Carlson MC, et al: Evidence for neurocognitive plasticity in at-risk older adults: the experience corps program. J Gerontol A Biol Sci Med Sci 2009; 64: 1275-1282.